Uptake of the traditional use registration scheme and implementation of the provisions of Directive 2004/24/EC in EU Member States

Similar documents
Overview of assessment work - Priority list

Brussels, January EUROCAM. Rue du Trône Brussels. Belgium T: E:

Meeting report, September 2005

The new European legislation on traditional herbal medicines: main features and perspectives

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SERBIA

Smokefree Policies in Europe: Are we there yet?

Inventory of herbal substances for assessment

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Cross Border Genetic Testing for Rare Diseases

Overview of drug-induced deaths in Europe - What does the data tell us?

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Inventory of herbal substances for assessment

European Collaboration on Dementia. Luxembourg, 13 December 2006

Regulatory aspects of Herbal Medicinal Products. and Supplements in EU / the Netherlands. Ir. Theo van Rooij

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

LEBANON. WCPT COUNTRY PROFILE December 2018

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

DENMARK. WCPT COUNTRY PROFILE December 2018

This document is a preview generated by EVS

Monthly measles and rubella monitoring report

Opinion of the HMPC on a European Union herbal monograph on Vitis vinifera L., folium

GERMANY. WCPT COUNTRY PROFILE December 2018

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

Nutrient profiles for foods bearing claims

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Where do EU Contries set the limit for low risk drinking.

Engagement in language assessment / Regions of Europe

Alcohol-related harm in Europe and the WHO policy response

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

Q1 What age are you?

The health economic landscape of cancer in Europe

'SECTION B EU PARTY. The following abbreviations are used:

Where we stand in EFORT

MEDICINAL PLANTS ISHA BOOKS DELHI-U (In 2 Volumes) (Volume-1) Editors Manisha, Vibha

Overall survival: 1 st line therapy

UK bowel cancer care outcomes: A comparison with Europe

European status report on alcohol and health Leadership, awareness and commitment

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

Rheumatoid Arthritis Disease Burden and Access to Treatment

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

The cancer burden in the European Union and the European Region: the current situation and a way forward

Outcome of proficiency test on EIA serology

Authorisation and registration of Herbal medicinal products and traditional herbal medicinal products. National and Community regulation.

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

Underage drinking in Europe

As adopted by HMPC 2006

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014

REPORT ON LAWS AND RECOMMENDATIONS ON DENTAL MERCURY MANAGEMENT IN THE EU

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

GLP in the European Union Ecolabel detergents, GLP and accreditation

SOITC Press Ad FAQs. Q: When will these Terms and Conditions changes come into effect?

L 322/24 Official Journal of the European Union

real-time AQ data 2007 and plans for 2008

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD AND FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR 2015

European Status report on Alcohol and Health

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Transmission, processing and publication of HBS 2015 data

Lymphogranuloma venereum

Opinion of the HMPC on a European Union herbal monograph on Crataegus spp., folium cum flore

National Food Chain Safety Office. Directorate of Veterinary Medicinal Product 1107 Budapest, Szállás u. 8. Hungary MUTUAL RECOGNITION PROCEDURE

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL ON FOOD INGREDIENTS TREATED WITH IONISING RADIATION FOR THE YEAR 2012

COMMISSION OF THE EUROPEAN COMMUNITIES

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

Trends in injecting drug use in Europe

We are IntechOpen, the first native scientific publisher of Open Access books. International authors and editors. Our authors are among the TOP 1%

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

CEN/TC 264/WG 39. Ambient air Sampling and analysis of airborne pollen grains and mold spores of allergy networks Volumetric Hirst method

Review of Member State approaches to the Macrophyte and Phytobenthos Biological Quality Element in lakes

CNAPA Meeting Luxembourg September 2016

Direction générale Médicaments

Project Meeting Prague

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

List of nationally authorised medicinal products

Alcohol Prevention Day

Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers

EFSA s activities on data collection (Art. 33) and proposal for a new initiative (EUMENU) H. Deluyker Director

PLACEMENT AND TREATMENT OF MENTALLY ILL OFFENDERS LEGISLATION AND PRACTICE IN EU-MEMBER STATES

Present and potential perspectives for information on alcohol use in the EU

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

European Community Pharmacy: a reference in Public Health

Hepatitis A SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Shigellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

MEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

Syphilis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe

Differences make a Difference

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

The Identification of Food Safety Priorities using the Delphi Technique

Transcription:

18 April 2017 EMA/HMPC/322570/2011 Rev. 7 Inspections, Human Medicines, Pharmacovigilance and Committees Division Uptake of the traditional use registration scheme and implementation of the provisions of Directive 2004/24/EC in EU Member States Status: 31 December 2016 Summary The provisions for registration of traditional herbal medicinal products in the European Union can be found in Chapter 2a of Directive 2001/83/EC that was introduced by Directive 2004/24/EC in April 2004. Regular reports on the uptake of the traditional use registration (TUR) scheme in the EU Member States 1 are published following the adoption of an Action plan for herbal medicines 2010-2011 by the management board of the European Medicines Agency and the Heads of Agencies (HMA) in 2010. During the latest survey (status 31 December 2016), National competent authorities (NCAs) provided the number of TUR granted for traditional herbal medicinal products (THMP) according to Art. 16a of Directive 2001/83/EC (Figures 1 and 3) and on marketing authorisations for herbal medicinal products (HMP) on the basis of well-established use (WEU MA) according to Art. 10a of Directive 2001/83/EC (Figures 2 and 4). Information was collected for both, monocomponent and combination products (products that contain more than one herbal substance/preparation as active substance). Furthermore it was specified for each Member State how many applications have been received, are under assessment, have been refused by NCAs, or withdrawn by applicants before authorisation (Tables 1 and 2, Figures 5 and 6). Based on additional information such as registration/authorisation dates, the active substance, and the indication, overviews are presented on the herbal substances used in monocomponent products (Tables 3 and 4), the number of components in combination products (Figure 7) and the traditional therapeutic areas to which granted indications can be allocated (Figures 8 and 9). All data are summarised in the report as received from NCAs of the EU Member States. For questions with respect to presented numbers or background information the NCAs may be contacted directly. General information on the registration of THMP can be found at the European Commission website: http://ec.europa.eu/health/human-use/herbal-medicines/index_en.htm https://ec.europa.eu/health/human-use/herbal-medicines/developments_en 1 EEA countries (European Economic Area) are included in this report EMA/HMPC/322570/2011 Rev. 7 Page 1/11

Figure 1 Number of traditional use registrations (TUR) for THMP in the EU grouped by year of registration for monocomponent and combination products (2004 until December 2016; total 1719). Figure 2 Number of well-established use marketing authorisations (WEU MA) for HMP in the EU grouped by year of authorisation for monocomponent and combination products (2004 until December 2016; total 859). EMA/HMPC/322570/2011 Rev. 7 Page 2/11

Figure 3 Number of granted TUR for monocomponent and combination THMP in EU Member States (since implementation of Dir. 2004/24/EC until 31 December 2016). Total 1719: 1089 for monocomponent products, 630 for combination products (No TUR granted for IS, LI, LU and MT). Figure 4 Number of granted WEU MA for monocomponent and combination HMP in EU Member States (since implementation of Dir. 2004/24/EC until 31 December 2016). Total 859: 704 for monocomponent products, 155 for combination products (No WEU MA granted for IS, IT, LI, LU and MT). EMA/HMPC/322570/2011 Rev. 7 Page 3/11

Table 1 Number of TUR applications for THMP according to Art. 16a Directive 2001/83/EC received, under assessment, granted, refused and withdrawn in EU Member States since national implementation of Directive 2004/24/EC until 31 December 2016. Member State Received Under assessment TUR granted TUR refused Withdrawn 1 Total 2730 574 1719 240 197 Austria 224 14 209 0 1 Belgium 72 26 28 7 11 Bulgaria 33 14 16 2 1 Croatia 38 12 24 0 2 Cyprus 8 6 2 0 0 Czech Republic 76 6 61 3 6 Denmark 18 11 2 4 1 Estonia 14 1 13 0 0 Finland 30 6 13 1 10 France 171 127 33 0 11 Germany 513 61 285 106 61 Greece 34 8 13 5 8 Hungary 115 50 65 0 0 Ireland 85 35 49 0 1 Italy 19 1 12 2 4 Latvia 25 0 21 0 4 Liechtenstein 2 0 0 0 0 0 Lithuania 32 0 14 15 3 Luxembourg 3 0 0 0 0 0 Malta 0 0 0 0 0 Netherlands 80 13 54 2 11 Poland 315 62 215 19 19 Portugal 20 7 12 0 1 Romania 33 25 8 0 0 Slovakia 16 5 5 2 4 Slovenia 34 4 26 0 4 Spain 162 7 100 54 1 Sweden 87 5 76 0 6 United Kingdom 450 58 348 18 26 (Norway) 26 10 15 0 1 (Iceland) 0 0 0 0 0 1 Withdrawn by applicant before registration 2 Liechtenstein has an agreement with Austria regarding recognition of registration issued by Austria 3 No response received EMA/HMPC/322570/2011 Rev. 7 Page 4/11

Table 2 Number of WEU MA applications for HMP according to Art. 10a Directive 2001/83/EC received, under assessment, granted, refused and withdrawn in EU Member States since national implementation of Directive 2004/24/EC until 31 December 2016. Member State Received Under assessment WEU MA granted WEU MA refused Withdrawn 1 Total 1354 303 803 64 181 Austria 74 18 56 0 0 Belgium 39 12 22 1 4 Bulgaria 15 3 12 0 0 Croatia 73 13 41 7 12 Cyprus 6 5 1 0 0 Czech Republic 73 16 36 6 15 Denmark 21 13 7 1 0 Estonia 13 0 8 0 5 Finland 35 8 10 0 17 France 59 30 25 0 4 Germany 2 447 67 286 24 67 Greece 26 5 16 1 4 Hungary 44 16 23 0 5 Ireland 7 2 4 0 1 Italy 3 0 0 2 1 Latvia 32 4 26 0 2 Liechtenstein 3 0 0 0 0 0 Lithuania 61 10 26 9 16 Luxembourg 4 0 0 0 0 0 Malta 0 0 0 0 0 Netherlands 35 4 23 1 7 Poland 65 24 27 2 12 Portugal 28 5 14 6 3 Romania 66 37 29 0 0 Slovakia 35 3 28 4 0 Slovenia 53 4 49 0 0 Spain 45 12 33 0 0 Sweden 56 4 46 0 6 United Kingdom 4 3 1 0 0 (Norway) 13 3 10 0 0 (Iceland) 0 0 0 0 0 1 Withdrawn by applicant before authorisation 2 3 MAs ceased because of sunset clause 3 Liechtenstein has an agreement with Austria regarding recognition of MA issued by Austria 4 No response received EMA/HMPC/322570/2011 Rev. 7 Page 5/11

Figure 5 Number of TUR applications for THMP received (total bar height), divided according to the current status (under assessment, granted, refused and withdrawn) in EU Member States (status 31 December 2016; see also Table 1). Figure includes only EU Member States with at least 30 applications for TUR and / or WEU MA. Figure 6 Number of WEU MA applications for HMP received (total bar height), divided according to the current status (under assessment, granted, refused and withdrawn) in EU Member States (status 31 December 2016; see also Table 2). Figure includes only EU Member States with at least 30 applications for TUR and / or WEU MA. EMA/HMPC/322570/2011 Rev. 7 Page 6/11

Table 3 Number of TUR for herbal substances used in monocomponent THMP in the EU by 31 December 2016 and current status/outcome of the corresponding HMPC assessment. Herbal substances 1 TUR 2 Status HMPC Draft monograph Final monograph assessment 3 publication date 4 publication date (TU/WEU) 5 (/LE/PS) 6 Total (162) 1066 Harpagophyti radix 65 F 10/01/2008 06/11/2008 TU (15/02/2016) (14/11/2016) Pelargonii radix 61 F 26/04/2011 04/02/2013 TU (26/10/2015) Valerianae radix 54 F 20/09/2005 26/10/2006 TU+WEU (23/07/2015) (27/04/2016) Hyperici herba 46 F 06/11/2008 20/12/2009 TU+WEU Thymi herba 42 F 08/05/2007 30/10/2007 TU (12/11/2013) (02/06/2014) Passiflorae herba 40 F 07/03/2007 07/09/2007 TU (25/01/2014) (18/06/2014) Ginseng radix 26 F 16/04/2013 22/05/2014 TU Salviae officinalis folium 26 F 16/07/2009 28/01/2011 TU Echinaceae purpureae radix 25 F 14/01/2009 03/02/2010 TU Silybi mariani fructus 25 PF 23/07/2015 Crataegi folium cum flore 23 F 14/10/2014 17/06/2016 TU Cucurbitae semen 22 F 17/10/2011 25/03/2013 TU Hippocastani semen 21 F 04/09/2008 16/07/2009 TU+WEU Cynarae folium 20 F 18/01/2011 21/12/2011 TU Melissae folium 20 F 08/05/2007 31/10/2007 TU (05/08/2013) Agni casti fructus 19 F 17/09/2009 05/08/2011 TU+WEU Rhodiolae roseae rhizoma et 19 F 22/08/2013 22/07/2014 TU radix Arnicae flos 17 F 20/09/2011 29/05/2012 TU Ginkgo folium 16 F 14/02/2014 08/04/2015 TU+WEU Matricariae flos 16 PF 24/07/2014 Plantaginis lanceolatae folium 14 F 15/11/2008 24/02/2012 TU Echinaceae purpureae herba 13 F 08/05/2007 08/05/2008 TU+WEU +LE (09/2014) (13/04/2015) Equiseti herba 13 F 30/10/2007 03/07/2008 TU (27/07/2015) (17/03/2016) Vitis viniferae folium 13 F 20/12/2009 03/01/2011 TU+WEU +LE Hederae helicis folium 12 F 08/03/2010 19/04/2011 TU+WEU (12/02/2015) (18/01/2016) Menthae piperitae folium 12 F 05/07/2007 05/07/2007 TU Visci albi herba 12 F* PS Tanaceti parthenii herba 11 F 28/05/2010 20/01/2011 TU Cimicifugae rhizoma 10 F 17/09/2009 20/01/2011 WEU Lichen islandicus 10 F 19/05/2014 11/02/2015 TU Urticae folium 10 F 08/05/2008 17/01/2011 TU 1 Herbal substance or preparation thereof used as single active substance in products with TUR 2 May include several TUR in different EU Member States for the same product 3 Status by April 2017 (R: Rapporteur assigned, D: Draft under discussion, P: Draft published, PF: Assessment close to finalisation [pre-final], F: Final opinion adopted, F*: Final Public Statement, C: Call for scientific data, n.p.: not on the HMPC priority list (EMA/HMPC/278067/2006) 4 In brackets the publication date of the revised monograph 5 Existing monograph for traditional use (TU), well-established use (WEU) or both (TU + WEU) 6 HMPC assessment outcome (: monograph, LE: list entry, PS: public statement) EMA/HMPC/322570/2011 Rev. 7 Page 7/11

Table 3 (continued) Herbal substances 1 TUR 2 Status HMPC Draft monograph Final monograph assessment 3 publication date 4 publication date (TU/WEU) 5 (/LE/PS) 6 Uvae ursi folium 10 F 16/06/2008 19/04/2011 TU Zingiberis rhizoma 10 F 20/09/2011 04/06/2012 TU+WEU Rosmarini aetheroleum 9 F 16/07/2009 28/01/2011 TU Sabalis serrulatae fructus 9 F 19/08/2013 06/08/2014 TU Rusci aculeati rhizoma 8 F 07/09/2007 04/09/2008 TU Fucus vesiculosus 8 F 10/09/2014 14/01/2016 TU+WEU Tiliae flos 8 F 20/10/2011 10/07/2012 TU Calendulae herba 7 C Menthae piperitae 7 F 31/10/2007 08/05/2007 TU+WEU +LE aetheroleum Orthosiphonis folium 7 F 16/07/2009 03/01/2011 TU Althaeae radix 6 F 03/07/2008 14/05/2009 TU (11/12/2015) (04/11/2016) Urticae radix 6 F 19/10/2011 05/11/2012 TU Allii sativi bulbus 5 P 25/07/2016 Eleutherococci radix 5 F 05/07/2007 08/05/2008 TU +LE (25/03/2014) (06/10/2014) Lavandulae aetheroleum 5 F 11/02/2011 13/06/2012 TU Liquiritiae radix 5 F 19/08/2011 24/08/2012 TU Millefolii herba 5 F 09/11/2010 30/09/2011 TU Myrtilli fructus recens 5 F 09/02/2015 09/12/2015 TU Taraxaci radix 5 n.p. Damianae folium 5 n.p. Absinthii herba 4 F 06/11/2008 16/07/2009 TU Arctii radix 4 F 08/03/2010 03/01/2011 TU Betulae folium 4 F 08/05/2007 08/05/2008 TU (24/11/2014) (13/03/2015) Calendulae flos 4 F 05/07/2007 08/05/2008 TU +LE Hamamelidis cortex 4 F 05/11/2008 23/03/2010 TU Lupuli flos 4 F 05/07/2007 11/07/2008 (07/08/2014) Piceae summitates 4 n.p. Quercus cortex 4 F 08/03/2010 28/01/2011 TU Solidaginis virgaureae herba 4 F 31/10/2007 04/09/2008 TU Trigonellae foenugraeci 4 F 10/06/2010 23/02/2011 TU semen Boldi folium 4 F 08/05/2008 (09/2016) 13/01/2009 (12/01/2017) TU Other 12 substances with 3 12 x 3 (F: 7, F*: 1, PF: 0, P: 0, D: 0, R: 0, C: 1, n.p.: 3) registrations Other 30 substances with 2 registrations 30 x 2 (F: 21, PF: 0, P: 0, D: 0, R: 0, C: 0, n.p.: 9) Other 58 substances with 1 registration 58 x 1 (F: 26, F*: 3, PF: 0, P: 0, D:2, R: 0, C: 1, n.p.: 26) TU 1 Herbal substance or preparation thereof used as single active substance in products with TUR 2 May include several TUR in different EU Member States for the same product 3 Status by April 2017 (R: Rapporteur assigned, D: Draft under discussion, P: Draft published, PF: Assessment close to finalisation [pre-final], F: Final opinion adopted, F*: Final Public Statement, C: Call for scientific data, n.p.: not on the HMPC priority list (EMA/HMPC/278067/2006) 4 In brackets the publication date of the revised monograph 5 Existing monograph for traditional use (TU), well-established use (WEU) or both (TU + WEU) 6 HMPC assessment outcome (: monograph, LE: list entry, PS: public statement) EMA/HMPC/322570/2011 Rev. 7 Page 8/11

Table 4 Number of WEU MA for herbal substances used in monocomponent HMP in the EU by 31 December 2016 and current status/outcome of the corresponding HMPC assessment. Herbal substances 1 WEU Status HMPC Draft monograph Final monograph MA 2 assessment 3 publication date 4 publication date (TU/WEU) 5 (/LE/PS) 6 Total (61) 694 Hederae helicis folium 115 F 08/03/2010 19/04/2011 TU+WEU (12/02/2015) (18/01/2016) Ginkgo folium 111 F 14/02/2014 08/04/2015 TU+WEU Valerianae radix 57 F 20/09/2005 26/10/2006 TU+WEU (23/07/2015) (27/04/2016) Hyperici herba 50 F 06/11/2008 20/12/2009 TU+WEU Silybi mariani fructus 33 PF 23/07/2015 Cimicifugae rhizoma 30 F 17/09/2009 20/01/2011 WEU Echinaceae purpureae herba 29 F 08/05/2007 08/05/2008 TU+WEU +LE (09/2014) (13/04/2015) Vitis viniferae folium 21 F 20/12/2009 03/01/2011 TU+WEU +LE Glycini semen 19 D 28/02/2017 Pelargonii radix 18 F 26/04/2011 04/02/2013 TU (26/10/2015) Sabalis serrulatae fructus 17 F 10/09/2014 14/01/2016 TU+WEU Sennae folium 17 F 10/01/2006 26/10/2006 WEU Crataegi folium cum flore 13 F 14/10/2014 17/06/2016 TU Hippocastani semen 12 F 04/09/2008 16/07/2009 TU+WEU Capsici fructus 10 F 12/09/2014 26/06/2015 WEU Visci albi herba 8 F* PS Plantaginis ovatae semen 8 F 24/10/2005 26/10/2006 WEU (11/2012) (23/07/2013) Psyllii semen 8 F 24/10/2005 26/10/2006 WEU (03/2013) (29/07/2013) Sennae fructus 8 F 10/01/2006 26/10/2006 WEU Agni casti fructus 7 F 17/09/2009 05/08/2011 TU+WEU Eucalypti aetheroleum 7 F 31/07/2013 13/05/2014 TU Passiflorae herba 6 F 07/03/2007 07/09/2007 TU (25/01/2014) (18/06/2014) Betulae folium 6 F 08/05/2007 08/05/2007 TU (24/11/2014) (13/03/2015) Solidaginis virgaureae herba 6 F 31/10/2007 04/09/2008 TU Camelliae sinensis non 6 F 19/04/2013 29/04/2014 TU fermentatum folium Thymi herba 5 F 08/05/2007 30/10/2007 TU (12/11/2013) (02/06/2014) Cynarae folium 5 F 18/01/2011 21/12/2011 TU Symphyti radix 5 F 19/08/2011 05/06/2015 TU Menthae piperitae aetheroleum 4 F 31/10/2007 08/05/2007 TU+WEU +LE Rhei radix 4 F 05/07/2007 30/10/2007 WEU Other 5 substances with 3 MA 5 x 3 (F: 4, PF: 0, P: 0, D: 0, R: 0, C: 1, n.p.: 0) Other 8 substances with 2 MA 8 x 2 (F: 4, PF: 0, P: 1, D: 0, R: 0, C: 0, n.p.: 3) Other 18 substances with 1 MA 18 x 1 (F: 10, F*: 1, PF: 0, P: 0, D: 0, R: 0, C: 1, n.p.: 6) 1 Herbal substance or preparation thereof used as single active substance in products with WEU MA 2 May include several WEU MA in different EU Member States for the same product 3 Status by April 2017 (R: Rapporteur assigned, D: Draft under discussion, P: Draft published, PF: Assessment close to finalisation [pre-final], F: Final opinion adopted, F*: Final Public Statement, C: Call for scientific data, n.p.: currently not on the HMPC priority list EMA/HMPC/278067/2006) 4 In brackets the publication date of the revised monograph 5 Existing monograph for traditional use (TU), well-established use (WEU) or both (TU + WEU). 6 HMPC assessment outcome (: monograph, LE: list entry, PS: public statement) EMA/HMPC/322570/2011 Rev. 7 Page 9/11

(* other includes e.g. combinations with ancillary vitamins or minerals) Figure 7 Number of TUR and WEU MA in the EU by 31 December 2016 for herbal combination products (total: 630 TUR; 155 WEU MA) grouped according to number of components (herbal substances and/or preparations) included. EMA/HMPC/322570/2011 Rev. 7 Page 10/11

Figure 8 Number of indications 1 granted in TUR for THMP grouped by typical traditional therapeutic areas 2 for monocomponent and combination products in the EU by 31 December 2016. Figure 9 Number of indications 1 granted in WEU MA for HMP grouped by typical traditional therapeutic areas 2 for monocomponent and combination in the EU by 31 December 2016. 1 May include several indications per registration/authorisation 2 May include several registrations/authorisations in different Member States for the same product Allocations of indications to the therapeutic areas in line with document EMA/568320/2009 Rev.1 used for browse by use function at the EMA website. (* Other includes indications in therapeutic areas so far not covered in document EMA/568320/2009 Rev.1 such as cardiovascular, improving liver function, mild cerebral insufficiencies) EMA/HMPC/322570/2011 Rev. 7 Page 11/11